Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1387845 | 0.90 | AR (0.62) | ARPGR | |
| SCHEMBL1388967 | 0.90 | AR (0.66) | ARPGR | |
| SCHEMBL8174011 | 0.88 | AR (0.61) | ARPGR | |
| SCHEMBL29921612 | 0.88 | AR (0.78) | ARPGR | |
| SCHEMBL4029305 | 0.88 | AR (0.78) | ARPGR | |
| SCHEMBL1387685 | 0.87 | AR (0.66) | ARPGR | |
| SCHEMBL1968224 | 0.83 | AR (0.75) | ARPGR | |
| SCHEMBL1712052 | 0.83 | AR (0.61) | ARPGR | |
| SCHEMBL8174734 | 0.83 | AR (0.57) | ARPGR | |
| SCHEMBL8213681 | 0.82 | AR (0.64) | ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0738263-B1 | SUBSTITUTED PHENYLIMIDAZOLIDINES HAVING ANTIANDROGEN ACTIVITY | AVENTIS PHARMA SA (FR) | 2001-04-04 | — | — | EP | disclosed |
| US-5750553-A | ANTIANDROGENIC AGENTS | ROUSSEL UCLAF (FR) | 1998-05-12 | — | — | US | disclosed |
| EP-0738263-A1 | NOVEL OPTIONALLY SUBSTITUTED PHENYLIMIDAZOLIDINES, INTERMEDIATES AND PROCESS FOR THEIR PREPARATION, THEIR USE AS DRUGS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ROUSSEL UCLAF (FR) | 1996-10-23 | — | — | EP | disclosed |
| WO-1995018794-A1 | NOVEL OPTIONALLY SUBSTITUTED PHENYLIMIDAZOLIDINES, INTERMEDIATES AND PROCESS FOR THEIR PREPARATION, THEIR USE AS DRUGS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ROUSSEL UCLAF (FR) | 1995-07-13 | — | — | WO | disclosed |